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Pharma Global Development, Leiden, The NetherlandsA B S T R A C TObjective: To assess the reliability and validity of scores derived from
the Patient Perception of Intensity of Urgency Scale (PPIUS) in patients
with lower urinary tract symptoms (LUTS) associated with benign
prostatic hyperplasia (BPH). Methods: A post hoc analysis of the
phase II Solifenacin and Tamsulosin in Males with Lower Urinary
Tract Symptoms Associated with Benign Prostatic Hyperplasia trial
(NCT00510406), a 12-week clinical trial in men with LUTS associated
with BPH, assessed the measurement properties of six PPIUS-derived
scores: mean score; maximum urgency score; total urgency and
frequency score (TUFS; average sum of urgency scores over 3 days);
and numbers of urgency episodes, urgency episodes of grade 3 or 4,
and urgency incontinence episodes. Test-retest reliability, presence of
ﬂoor/ceiling effects, responsiveness to change, known-group validity,
and concurrent validity were assessed for each score. Results: A total
of 901 patients had at least one valid PPIUS assessment after baseline.
TUFS demonstrated good test-retest reliability (intraclass correlation
coefﬁcient 40.8), discriminated between groups deﬁned based onee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.09.002
@healthoutcomessolutions.com.
ndence to: Susan D. Mathias, Health Outcomes SoInternational Prostate Symptom Score storage score severity (known-
groups validity), had high concurrent validity, and had high respon-
siveness to change (Guyatt’s responsiveness statistic 0.88), with an
absence of ﬂoor or ceiling effects. The psychometric properties of
other PPIUS-derived scores were not as consistently robust and
showed either low-to-moderate responsiveness, presence of a ﬂoor
or ceiling effect, or low-to-moderate test-retest reliability. Conclu-
sions: This study shows that the PPIUS is reliable and valid in
patients with LUTS associated with BPH. TUFS provided the best
combination of psychometric properties of the six scores derived from
the PPIUS and appeared to be an appropriate measure of urgency and
frequency.
Keywords: benign prostatic hyperplasia, lower urinary tract symptoms,
Patient Perception of Intensity of Urgency Scale, validation.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Lower urinary tract symptoms (LUTS) include storage symptoms,
such as increased daytime urinary frequency, nocturia, urinary
urgency, and urinary incontinence; voiding symptoms, including
weak stream, hesitancy, and terminal dribble; and postmictur-
ition symptoms, which include incomplete bladder emptying and
postmicturition dribble [1]. In a large population-based study
(Epidemiology of LUTS) conducted in Sweden, the United King-
dom, and the United States, the prevalence of LUTS, deﬁned as a
symptom frequency of at least “A few times per week,” was more
than 45% [1]. In men, LUTS are commonly associated with benign
prostatic hyperplasia (BPH) [2,3].
Patients are typically in the best position to identify and
describe their symptoms; therefore, the prevalence and impact
of LUTS are often investigated using information collected
directly from patients, through either surveys and questionnaires
[4,5] or assessment tools including diaries or logs [6–8]. LUTS havebeen shown to negatively affect health-related quality of life
(QOL) [9–11] because symptoms can cause signiﬁcant interference
with daily activities [12] and are associated with depression [11]
and decreased enjoyment of sexual activity [13].
Reliable and valid tools for collecting information and assess-
ing LUTS are essential. The Patient Perception of Intensity of
Urgency Scale (PPIUS) is a single-item, patient-reported scale that
can be used to assess the intensity of urgency associated with
each micturition or incontinence episode (Table 1) [14]. The PPIUS
uses information that patients provide regarding the frequency
and urgency of micturition and incontinence episodes, and
several scores can be derived from it. It was developed on the
basis of guidance from the European Medicines Agency and then
validated and used in clinical trials of therapies for overactive
bladder (OAB), including those of solifenacin and mirabegron
[8,14–22]. There are no reports, however, of its measurement
properties in men with LUTS associated with BPH. The objective
of this study was to assess the reliability and validity of differentociety for Pharmacoeconomics and Outcomes Research (ISPOR).
lutions, PO Box 2343, Winter Park, FL 32790, USA.
Table 1 – PPIUS and derived scores.
Response option Response label
0 No urgency
1 Mild urgency
2 Moderate urgency
3 Severe urgency
4 Urge incontinence
Derived score Description
Mean urgency score Average of individual urgency
scores over the 3-day
micturition diary period
Maximum urgency score Average of the maximum daily
urgency score over the 3-day
micturition diary period
Total urgency and
frequency score (TUFS)*
Mean of daily totals for all recorded
PPIUS urgency gradings (0–4) for
each micturition diary day
Mean number of urgency
episodes
Average number of instances with
a PPIUS score of Z1
Mean number of episodes
of urgency grade 3 or 4
Average number of instances with
a PPIUS score of Z3
Mean number of urgency
incontinence episodes
Average number of instances with
a PPIUS score of 4
PPIUS, Patient Perception of Intensity of Urgency Scale.
* Previously known as the total urgency score (TUS).
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LUTS associated with BPH.Methods
Study Design
A post hoc analysis of PPIUS data from a phase II, double-blind,
parallel-group, placebo-controlled, randomized study to assess
the safety and efﬁcacy of combinations of solifenacin and
tamsulosin in men with LUTS associated with BPH (the phase II
Solifenacin and Tamsulosin in Males with Lower Urinary Tract
Symptoms Associated with Benign Prostatic Hyperplasia trial)
was conducted. Full methodology, efﬁcacy, and safety data from
this trial have been reported previously [23]. Men aged at least 45
years diagnosed as having LUTS associated with BPH for at least 3
months, with a total International Prostate Symptom Score (IPSS)
of at least 13 (a cutoff widely used to select patients for clinical
trials of therapies for LUTS associated with BPH [23–26]), and a
maximum urinary ﬂow rate of 4 to 15 ml/s were eligible to enroll
in the study. Patients with signiﬁcant urinary, cardiovascular,
cerebrovascular, renal, or hepatic disease were excluded.
Assessments
Assessments completed by patients enrolled in the study
included the PPIUS; the IPSS [24], which, in addition to seven
symptom items, contains a single-item assessment of QOL due to
urinary symptoms (IPSS QOL); and the single-item Patient Per-
ception of Bladder Condition tool. Each assessment was self-
administered by the patient during clinic visits at screening, at
the end of a 2-week run-in period (baseline), and at weeks 2, 4, 8,
and 12 of treatment or at early termination.
Patients were asked to complete a 3-day micturition diary, in
which they recorded all micturition and incontinence episodes, at
home, before every visit. For every micturition and incontinenceepisode during the 3-day period, patients rated the degree of
urgency according to the PPIUS, a ﬁve-point categorical scale,
ranging from “No urgency” (a score of 0) to “Severe urgency” (a
score of 3) and “Urgency incontinence” (4). Six scores derived from
the PPIUS were evaluated (Table 1). The proportion of responses
for each urgency rating was also recorded.
Patients completed the seven-item IPSS [27], developed to
diagnose and assess the symptoms of BPH, at every visit. The
IPSS was developed by the Measurement Committee of the
American Urological Association and is recommended by the
World Health Organization for use with patients with LUTS
suggestive of BPH. It includes seven questions relating to the
frequency of the following symptoms: incomplete bladder emp-
tying, intermittency, weak stream, hesitancy, frequency,
urgency, and nocturia. Each question is scored using a range
from 0 to 5, where higher scores reﬂect increased symptom
severity. The IPSS storage subscore and individual urgency item
score were also calculated in this study. The IPSS also includes a
single QOL question regarding how patients perceive their
urinary condition, with responses ranging from “Delighted” (0)
to “Terrible” (6).
Patients also completed the single-item Patient Perception of
Bladder Condition, which asks patients to assess the amount of
bother their urinary condition causes, using response options
ranging from “Does not cause me any problems at all” (1) to
“Causes me many severe problems” (6).
Descriptive Analysis
Patients with valid PPIUS assessments, that is, the PPIUS was
completed correctly and PPIUS scores were calculated, at baseline
were included in the analysis. Descriptive analysis was used to report
demographic characteristics of the cohort including age, height,
weight, and body mass index (BMI). Counts and percentages were
calculated for race categories, history of smoking, and alcohol use.
Analysis of Measurement Properties
Measurement properties assessed included examination of
response characteristics, test-retest reliability, responsiveness,
known-groups validity, and concurrent validity. Internal consis-
tency reliability could not be calculated because the PPIUS
contains only a single item, and it was not possible to estimate
the minimal clinically important difference because there were
no anchors to which changes in PPIUS scores could be related.
Measurement properties were evaluated for the full sample and
for a subgroup of patients who reported substantial storage
symptoms at baseline. Substantial storage symptoms were deﬁned
as having a micturition frequency of at least eight episodes daily
and at least two episodes of urgency of grade 3 or 4 on average
per day over the 3-day diary period.
To examine the PPIUS response characteristics, the variability
in responses, including the number and percentage of patients
with the minimum (0) and maximum (4) possible scores, was
determined separately for the 3 days of diary ratings before
baseline and the end of treatment for all six scores (mean and
maximum urgency score, TUFS, and numbers of episodes of
urgency [PPIUS grade Z1], PPIUS grade 3 or 4, and urgency
incontinence episodes). In addition, the proportion of responses
for each urgency rating was determined separately by visit.
Baseline and end-of-treatment visits were selected because these
time points correspond to those for establishing efﬁcacy.
Test-retest reliability refers to the extent to which a measure
yields the same results in repeated applications in an unchanged
population. Test-retest reliability was assessed by calculating
intraclass correlation coefﬁcients (ICCs) [28] between daily ratings
on the PPIUS for 3 consecutive days before baseline. An ICC of at
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pairwise Wilcoxon signed rank test was used to determine whether
there were any signiﬁcant differences in ratings over the 3 days.
The responsiveness of a measure reﬂects its ability to detect
clinically important changes, even if the changes are small. This
was evaluated using three metrics. The standard effect size [29]
was calculated as the difference in means between baseline and
the end of treatment, divided by the standard deviation (SD) at
baseline. The magnitude of the effect was based on Cohen’s
deﬁnitions of small (0.20), medium (0.50), and large (0.80). The
standardized response mean [30] was calculated as the difference
in means between baseline and the end of treatment, divided by
the SD of the change score. Finally, the responsiveness statistic [31]
was calculated as the difference in means between baseline and
the end of treatment, divided by the SD of the change score for
stable patients. Values of 0.20 and 0.50 were used to indicate
“small” and “medium” changes, respectively. For the responsive-
ness statistic, two methods were used to deﬁne the SD for stable
patients. The ﬁrst used the SD for those patients experiencing a 0%
to 20% change in the mean number of urgency episodes per 24
hours from baseline to the end of treatment, whereas the second
used the SD of the change at the end of treatment from the
previous visit for placebo patients.
Known-groups validity is the extent to which a measure is able
to discriminate between groups known to be clinically different.
Two groups based on symptom severity were created using the
median IPSS storage score at baseline and the end of treatment:
patients at or below the median were placed into one group,
whereas those above the median were placed in the other group.
The known-groups validity of the PPIUS at baseline and the end of
treatment was then evaluated by comparing PPIUS scores between
severity groups. Comparisons at each time point were made using
analysis of covariance controlling for age. Adjusted means and SDs
were calculated separately by group for each PPIUS score. Partial ε2
values, which express the proportion of variance of the dependent
variable accounted for by group membership, were also calculated
for each score at each time point.
A measure is considered to have adequate concurrent validity
if it can be shown to be associated with conceptually related
criterion measures. The concurrent validity of the PPIUS was
examined in several ways. First, Spearman and Pearson correla-
tion coefﬁcients between baseline values of PPIUS and each of the
following baseline scores were calculated: IPSS storage subscore,
IPSS urgency item score, IPSS QOL score, and Patient Perception
of Bladder Condition. Second, Spearman and Pearson correlation
coefﬁcients between the change in baseline-to-end of treatment
PPIUS scores and the change in each of the above variables during
that same time period were calculated.Table 2 – PPIUS response characteristics.
Response characteristic Time point
Mean PPIUS score Baseline
End of treatment
Maximum PPIUS score Baseline
End of treatment
TUFS Baseline
End of treatment
Urgency episodes Baseline
End of treatment
Urgency episodes of grade 3 or 4 Baseline
End of treatment
Urgency incontinence episodes Baseline
End of treatment
PPIUS, Patient Perception of Intensity of Urgency Scale; TUFS, total urgeResults
Patient Population and Descriptive Analysis
A total of 1010 patients with LUTS associated with BPH and
baseline PPIUS scores were included in the study. All participants
were men, and all but ﬁve were white. Their mean age was 65.6 
8.0 years (range 45–92 years), and their mean BMI was 27.7  4.0
kg/m2. Although BMIs ranged from 17.6 to 54.3 kg/m2, 23.5% of the
participants met the criterion for obesity (BMI 430 kg/m2). Only
13% of the participants were current smokers, and 63.3% were
current users of alcohol. A total of 901 patients had at least one
valid PPIUS assessment after baseline. Most of these patients (n ¼
862, 96%) had complete follow-up data, and therefore, end-of-
treatment PPIUS scores represent those at week 12. The remain-
ing patients terminated the study early, and their end-of-
treatment values are from assessments before the 12th week. A
total of 398 patients (40%) were included in the subgroup
analysis, with end-point data available for 360.Measurement Properties
A summary of PPIUS response characteristics is presented in Table 2.
The characteristics of the urgency incontinence episode scores in this
particular population are noteworthy: a high percentage of partic-
ipants reported the minimum possible score of 0 (i.e., the “ﬂoor”) at
baseline (79%), reﬂected in the median being 0. This would suggest
that measurement of urgency incontinence may not be sensitive for
detecting changes over time in the overall population of men with
LUTS associated with BPH. Assessing the change in this parameter
from baseline only in those patients who have urgency incontinence
at baseline may address the issue of the high baseline ﬂoor effect.
The test-retest reliability results for PPIUS scores reveal that
the highest ICC values were obtained for the mean PPIUS score,
which averaged above 0.90, followed by TUFS and episodes of
urgency of grade 3 or 4, which both averaged above 0.80 (Table 3).
ICC values for the remaining scores averaged below 0.80, suggest-
ing that they are somewhat less stable over time. All scores,
except the mean PPIUS and urgency incontinence episode scores,
demonstrated signiﬁcant changes from day 1 to 2, suggesting
that patients required some time to become accustomed to the
diary recording procedures. Even though these changes were
statistically signiﬁcant, they were relatively small in magnitude
(o0.08), indicating that the changes would likely not affect the
validation of the PPIUS in this sample.
When examining the responsiveness statistics (Fig. 1), three
scores show notably higher values than do other scores across alln Mean  SD Median Range
1010 1.81  0.71 1.90 0–4.00
901 1.60  0.74 1.71 0–3.90
1010 2.59  0.81 2.67 0–4.00
901 2.20  0.91 2.00 0–4.00
1010 18.70  9.72 17.67 0–69.33
901 14.51  9.26 13.33 0–92.00
1010 9.22  3.30 9.00 0–22.33
901 7.78  3.41 8.00 0–25.00
1010 2.51  3.08 1.33 0–18.67
901 1.51  2.73 0.00 0–25.00
1010 0.33  1.10 0 0–12.33
901 0.16  0.92 0 0–17.00
ncy and frequency score.
Table 3 – Test-retest reliability of PPIUS scores at baseline.
Response characteristic Days compared* Mean 1 Mean 2 ICC (95% CI) P†
Mean PPIUS score 1 vs. 2 1.82 1.81 0.904 (0.892–0.914) 0.199
1 vs. 3 1.82 1.80 0.885 (0.871–0.898) 0.055
2 vs. 3 1.81 1.80 0.915 (0.904–0.924) 0.137
Maximum PPIUS score 1 vs. 2 2.63 2.58 0.751 (0.722–0.776) 0.011
1 vs. 3 2.63 2.56 0.748 (0.719–0.774) o0.001
2 vs. 3 2.58 2.56 0.786 (0.762–0.809) 0.296
TUFS 1 vs. 2 19.05 18.47 0.836 (0.817–0.854) 0.001
1 vs. 3 19.11 18.59 0.821 (0.800–0.840) 0.009
2 vs. 3 18.51 18.59 0.837 (0.817–0.854) 0.565
Urgency episodes 1 vs. 2 9.34 9.11 0.787 (0.762–0.809) 0.003
1 vs. 3 9.36 9.23 0.754 (0.726–0.780) 0.193
2 vs. 3 9.12 9.23 0.798 (0.775–0.820) 0.041
Urgency episodes of grade 3 or 4 1 vs. 2 2.60 2.49 0.832 (0.812–0.850) 0.042
1 vs. 3 2.60 2.46 0.826 (0.805–0.844) 0.016
2 vs. 3 2.49 2.46 0.836 (0.817–0.854) 0.162
Urgency incontinence episodes 1 vs. 2 0.31 0.34 0.749 (0.721–0.775) 0.462
1 vs. 3 0.31 0.35 0.801 (0.778–0.822) 0.154
2 vs. 3 0.34 0.35 0.798 (0.774–0.819) 0.821
CI, conﬁdence interval; ICC, intraclass correlation coefﬁcient; PPIUS, Patient Perception of Intensity of Urgency Scale; TUFS, total urgency and
frequency score.
* n for comparisons were as follows: day 1 vs. day 2: 1008; day 1 vs. day 3: 1006; day 2 vs. day 3: 1005.
† Based on Wilcoxon signed rank test.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 2 3 – 8 2 9826the responsiveness statistics. These are the maximum PPIUS
score, TUFS, and urgency episodes. The maximum PPIUS score
had the highest standard effect size and standardized response
mean, whereas TUFS produced the highest value for the respon-
siveness statistic.
Known-groups validity was assessed using data from baseline
and the end of treatment, grouping patients by severity on the basis
of the IPSS storage scores at the given time point. PPIUS scores wereMean PPIUS
score
0.31
0.36
0.64
0.84
0.49
0.55
0.88
0.45
0.54
Maximum
PPIUS score
TUFS
SES
1
0.8
0.6
0.4
0.2
0
Fig. 1 – Responsiveness of the PPIUS-derived scores at week 12
baseline and the end of treatment, divided by the SD at baselin
small (0.20), medium (0.50), and large (0.80). SRM was calculated
treatment, divided by the SD of the change score. The responsi
between baseline and the end of treatment, divided by the SD of
were used to indicate “small” and “medium” changes, respecti
SES, standard effect size; SRM, standard response mean; TUFS,signiﬁcantly higher for patients with higher severity (Table 4). At
both baseline and the end of treatment, partial ε2 values were
highest for TUFS (baseline ¼ 0.125; end of treatment ¼ 0.205) and
urgency episode grades 1 to 4 (baseline ¼ 0.111; end of treatment ¼
0.194), indicating that these two scores demonstrate the greatest
ability to discriminate between groups of differing severity.
Several PPIUS scores demonstrated signiﬁcant associations
with conceptually related measures, indicating concurrent0.74
0.46
0.53
0.71
0.34
0.40
0.48
0.16 0.15
SRM Responsiveness statistic
Urgency
episodes
Urgency
episodes of
grade 3 or 4
Urge
incontinence
episodes
. SES was calculated as the difference in means between
e. Magnitude of effect was based on Cohen’s deﬁnitions of
as the difference in means between baseline and the end of
veness statistic was calculated as the difference in means
the change score for stable patients. Values of 0.20 and 0.50
vely. PPIUS, Patient Perception of Intensity of Urgency Scale;
total urgency and frequency score.
Table 4 – Known-groups validity.
Response characteristic
Baseline End of treatment
Group 1
(n ¼ 466)*
Group 2
(n ¼ 523)*
Partial ε2 Group 1
(n ¼ 481)*
Group 2
(n ¼ 411)* Partial ε2
Mean PPIUS score 1.66  0.65 1.96  0.72 0.044 1.41  0.72 1.80  0.71 0.069
Maximum PPIUS score 2.40  0.77 2.77  0.08 0.051 1.97  0.90 2.44  0.85 0.068
TUFS 15.08  7.59 21.98  10.26 0.125 10.65  6.15 18.68  9.53 0.205
Urgency episodes 8.05  2.72 10.24  3.40 0.111 6.37  2.76 9.34  3.30 0.194
Urgency episodes of grade 3 or 4 1.60  2.23 3.37  3.50 0.081 0.76  1.52 2.29  3.26 0.086
Urgency incontinence episodes 0.15  0.61 0.50  1.40 0.025 0.05  0.32 0.24  1.00 0.017
Note. Group 1: Patients whose IPSS storage score at that time point was at or below the median. Group 2: Patients whose IPSS storage score at
that time point was above the median. All P values for the known-groups validity comparisons are o0.001.
IPSS, International Prostate Symptom Score; PPIUS, Patient Perception of Intensity of Urgency Scale; TUFS, total urgency and frequency score.
* Values are mean  SD.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 2 3 – 8 2 9 827validity. Correlation coefﬁcients between the baseline PPIUS
scores and the baseline concurrent measures were all statistically
signiﬁcant (P o 0.001). The strongest relationship was demon-
strated by TUFS, with Spearman correlations ranging from 0.33
for both the IPSS urgency item and the IPSS QOL item scores to
0.47 for the IPSS storage subscore (data not shown). Correlations
between the baseline to end-of-treatment changes in PPIUS
scores and the concurrent measures were also all signiﬁcant
(P o 0.05), again with TUFS demonstrating the strongest associ-
ation (range 0.22–0.33).
A summary of the PPIUS validity measures is presented in
Table 5. Although several of the PPIUS scores demonstrate
adequate reliability and validity, TUFS stands out as consistently
performing better than most or all the other PPIUS scores for each
measurement property. The maximum PPIUS score and the
urgency episode score demonstrate moderate-to-high reliability
and responsiveness, followed by the mean PPIUS score and
episodes of urgency of grade 3 or 4, which perform moderately
well. The urgency incontinence episode score has consistently
poor responsiveness and validity in the overall population, with
limited ability to distinguish between patients of varying symp-
tom severity or to identify signiﬁcant changes within patients.
The analysis was also performed for the subgroup of patients
with substantial storage symptoms at baseline (n=398). As
expected, the baseline ﬂoor effect for urgency incontinence in
this population was lower than that in the overall population
(56% vs. 79%); similar results were observed in relation to the
baseline ﬂoor effect for urgency grade 3 or 4 (0% vs. 31%). Results
of the PPIUS validity analysis in this subgroup of patients with
substantial storage as well as voiding symptoms at baseline were
generally consistent with those of the full sample of patients with
LUTS associated with BPH (data not shown).Discussion
LUTS associated with BPH is common in the adult male popula-
tion, especially in those of advancing age. Having access to valid,
reliable, and easy-to-use tools to measure symptoms for patients
with LUTS is critical for both researchers and clinicians. Cur-
rently, the IPSS, a seven-item measure of symptom severity, is
most widely used to assess symptoms [27,32]. In contrast, the
PPIUS is a single-item scale and has been validated as a measure
of the urgency of micturition and incontinence episodes in
patients with OAB [14]. If shown to be reliable and valid in men
with LUTS, the PPIUS has potential advantages over the IPSS in
terms of its ease of use and the ability to derive various scores
from it. The current study provides evidence for the reliabilityand validity of the PPIUS in assessing the degree of urgency
associated with micturition and urgency incontinence episodes
in men with LUTS associated with BPH. The PPIUS demonstrates
adequate-to-good reliability, responsiveness to change, the abil-
ity to differentiate groups differing in severity, and agreement
with conceptually related measures in this population.
Of all the PPIUS-derived scores, TUFS appears to provide the
best combination of psychometric properties. This measure,
which takes both the level of urgency and the frequency into
account, thus including two key storage symptoms in a single
storage parameter, demonstrates good reliability and responsive-
ness, is able to differentiate among groups of differing severity
better than do other PPIUS scores, and has a stronger association
with other conceptually related measures at both baseline and
when assessing change from baseline. It should be noted, how-
ever, that urgency and episodes of urgency of grade 3 or 4 also
perform relatively well in the population of men with LUTS
associated with BPH, and may therefore continue to be relevant
for use in studies in this population. The high ﬂoor effect for
urgency episodes of grade 3 or 4, that is, the proportion of men
with no or mild urgency at baseline, may have had an inﬂuence
on the responsiveness of this measure in this study as compared
with studies of patients with OAB, in which assessment of
urgency episodes of grade 3 or 4 is a key measure of disease
burden. Because ﬂoor effects make it harder to detect changes
over time, the responsiveness observed for urgency episodes of
grade 3 or 4 supports its relevance. The ﬂoor effect was reduced
in the subgroup of patients with substantial storage symptoms as
well as voiding symptoms at baseline, consistent with the effect
seen in patients with OAB; TUFS also provided the best combi-
nation of psychometric properties in this subgroup.
The statistically signiﬁcant reduction in mean PPIUS scores
between days 1 and 2 of the micturition diary before baseline
may suggest that steps could be taken to try to improve
consistency. The idea of teaching patients how to complete a
micturition diary has been previously explored, but with mixed
results, as discussed by Cartwright et al. [19]. Alternatively, it may
be that patients will provide a more accurate assessment of
symptoms if given at least 1 day to practice recordings before the
data are used for analysis.
Although this study provides a comprehensive examination of
the measurement properties of the PPIUS in patients with LUTS
associated with BPH, its limitations should be noted. First,
although test-retest reliability typically requires multiple assess-
ments of untreated patients 7 to 14 days apart, participants in
this study were being treated, and the data best suited to
examining test-retest reliability were obtained on 3 consecutive
days while patients were receiving placebo run-in medication
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 2 3 – 8 2 9828rather than on separate occasions while patients were not
receiving therapy. Although not ideal, these measures did allow
for an initial examination of reliability. Another limitation is that
no anchors were available to establish a minimally important
clinical difference; speciﬁcally, the correlation between the IPSS
and the PPIUS was not uniformly high enough (40.30) for the
IPSS to be an appropriate anchor. Once one is established,
however, it will enhance the ability to characterize interindivid-
ual and intraindividual changes.
In summary, this study uses data from a large phase II clinical
trial to provide evidence of the reliability and validity of the PPIUS
in assessing urgency in men with LUTS associated with BPH.
Given the prevalence of LUTS worldwide, its association with age,
and variations in practice patterns in the diagnosis and treat-
ment of BPH, it is crucial to be able to assess LUTS reliably and
accurately. This is particularly important because evidence
shows that physicians may be underutilizing currently available
clinical assessments for LUTS and that the storage component of
LUTS is underrecognized in men with BPH [33,34]. The PPIUS is a
single-item scale that is reliable and valid, and it can be used with
conﬁdence in future research and clinical settings to assess
urinary urgency in men with LUTS and the impact of treatment.
TUFS, which takes both the level of urgency and frequency into
account, thus including two key storage symptoms in a single
storage parameter, appears to provide the best combination of
psychometric properties in men with LUTS associated with BPH.Acknowledgments
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